Inventiva S.A. (EPA:IVA)
France
· Delayed Price · Currency is EUR 3.195
-0.005 (-0.16%)
May 12, 2025, 5:35 PM CET
Inventiva Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue
14.09M
Revenue Growth
-38.24%
P/S Ratio
21.69
Revenue / Employee
121.50K
Employees
118
Market Cap
305.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
| Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
| Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 45.17B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| emeis Société anonyme | 5.64B |
Inventiva News
- 7 days ago - Inventiva secures €116 million second tranche of structured financing of up to €348 million - Seeking Alpha
- 8 days ago - Inventiva secures the €116 million second tranche of its structured financing of up to €348 million - GlobeNewsWire
- 12 days ago - Combined General Meeting of May 22, 2025 - Availability of the preparatory documents - GlobeNewsWire
- 18 days ago - Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor - GlobeNewsWire
- 27 days ago - Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F - GlobeNewsWire
- 5 weeks ago - Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis - GlobeNewsWire
- 6 weeks ago - Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Inventiva reports its 2024 full year results and provides a business update - GlobeNewsWire